StockData
Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc. (MIRM) stock

MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30
$92.49+0.54 (+0.59%)

Close on Nov 18, 2026Market cap $6.01BP/E –Yield –

Mirum Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Mirum Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $618.07M, up 44.0% year over year. For fiscal 2025 it was $521.31M, up 54.7% from the year before. The highest annual figure on record is $521.31M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$521.31M+54.7%
FY2024Dec 31, 2024$336.89M+80.8%
FY2023Dec 31, 2023$186.37M+141.8%
FY2022Dec 31, 2022$77.06M+302.7%
FY2021Dec 31, 2021$19.14M–
FY2020Dec 31, 2020$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$176.24M+37.9%
Q1 FY2026Mar 31, 2026$159.88M+43.3%
Q4 FY2025Dec 31, 2025$148.93M+49.8%
Q3 FY2025Sep 30, 2025$133.01M+47.2%
Q2 FY2025Jun 30, 2025$127.79M+64.1%
Q1 FY2025Mar 31, 2025$111.59M+61.2%
Q4 FY2024Dec 31, 2024$99.41M+42.9%
Q3 FY2024Sep 30, 2024$90.38M+89.4%
Q2 FY2024Jun 30, 2024$77.88M+179.1%
Q1 FY2024Mar 31, 2024$69.22M+268.6%
Q4 FY2023Dec 31, 2023$69.55M+297.8%
Q3 FY2023Sep 30, 2023$47.73M+270.2%
Q4 FY2022Dec 31, 2022$27.91M+789.3%
Q3 FY2022Sep 30, 2022$18.78M+275.6%
Q2 FY2022Jun 30, 2022$17.48M+58.9%
Q1 FY2022Mar 31, 2022$12.89M–
Q4 FY2021Dec 31, 2021$3.14M–
Q3 FY2021Sep 30, 2021$5.00M–
Q2 FY2021Jun 30, 2021$11.00M–
Q1 FY2021Mar 31, 2021$0–
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–

More Mirum Pharmaceuticals figures

See a number that looks wrong?